Immunobiology

The rapid evolution and expansion of applications in targeted cell therapies and immunobiologics has seen significant interest in the use of biological therapies for treating disease, resulting in an evolving and complex patent space. 

Challenges in product efficacy, administration, side effects and costs are driving ongoing research, with IP considerations spanning the preparation of cells, formulations and methods of administration. 

HGFs team of 23 life sciences attorneys, who possess specific immunobiology academic accomplishments and in-house backgrounds, apply a cross-technology approach to building portfolios and data-driven strategies that layer protection and maximise exclusivity periods. 

The team’s extensive insight into regulatory and approval pathways in this area adds a strong commercial focus to the development of economically viable strategies. Furthermore, the multidisciplinary specialists have significant experience in conducting due diligence across every aspect of immunobiology, from genes through to formulation and application processes. 

Working with universities, large pharmaceutical firms and generic companies, HGF creates and protects patents for commercially important products, with significant experience of opposition and appeals before the European Patent Office.

Latest updates

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

The Microbiome Times: ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …

Read article

Getting your first filing right

One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …

Read article

Start-ups & IP, a case study: SleepCogni

Using SleepCogni as a case study, we look at some key ways that IP can help start-ups to develop their technology and secure investment. SleepCogni is a SleepTech start-up who …

Read article
Event - 26th October 2021

9th Microbiome R&D and Business Collaboration Forum: Europe

9th Microbiome R&D and Business Collaboration Forum: Europe will be held on 26th-27th October 2021 in Rotterdam, The Netherlands. The event is dedicated to exploring microbiome research and strategies for …

Event details
Event - 21st October 2021

Medical Technology Ireland Conference 2021

Medical Technology Ireland Conference will be held on 20-21 October 2021 at the Galway Racecourse. Medical Technology Ireland Conference features presentations by leading international medical device experts with thought-provoking guest …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our immunobiology specialists.